PRECIGEN, INC. Adjustments to Additional Paid in Capital, Other
PRECIGEN, INC. (PGEN) reported Adjustments to Additional Paid in Capital, Other of -$1.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2026-03-25
- PRECIGEN, INC. adjustments to additional paid in capital, other for the quarter ending 2025-09-30 was -$1.30M.
- PRECIGEN, INC. adjustments to additional paid in capital, other for fiscal 2025 was -$1.30M.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month | Adjustments to Additional Paid in Capital, Other 12 month |
|---|---|---|
| 2025-12-31 | -$1.30M 10-K · filed 2026-03-25 | |
| 2025-09-30 | -$1.30M 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |